Decoy (DCOY) pursues pan‑filovirus D‑MAV program via FDA Animal Rule after in‑vitro Ebola/Marburg activity
AI Summary
Decoy (DCOY) said it is advancing a pan‑filovirus Designable Multi‑Antiviral (D‑MAV) program via the FDA Animal Rule pathway while seeking non‑dilutive government grants and public‑health partnerships and targeting Priority Review Voucher (PRV) monetization. A first‑generation de novo candidate showed low‑micromolar IC50 against wild‑type Ebola Zaire (reported >5x potency vs its prior pan‑coronavirus lead and ~7x vs remdesivir) and demonstrated activity against Marburg; the platform is being engineered for extended tissue residence that could support infrequent dosing. All results are preclinical (in vitro) — Decoy has not announced INDs, clinical efficacy data, or secured non‑dilutive funding, and Animal Rule approval would require successful animal efficacy plus human safety/PK data.
Positives
- First‑generation candidate showed low‑micromolar IC50 vs wild‑type Ebola Zaire and activity vs Marburg in cell assays
- Reported >5x potency improvement vs prior pan‑coronavirus lead and ~7x improvement vs remdesivir benchmark
- Company is targeting FDA Animal Rule to enable expedited approval and pursuing non‑dilutive grants/partnerships with potential PRV value
Negatives
- Data are preclinical in vitro only; no clinical efficacy or human data disclosed
- No IND filings or specific secured non‑dilutive funding announced
- Animal Rule path still requires well‑controlled animal efficacy studies and human safety/PK — approval is not guaranteed